Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

NEW YORK – Sensorion on Monday said that by year end it expects to complete dosing the first cohort of pediatric patients with congenital hearing loss with its gene therapy candidate SENS-501 in the ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).

If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.

The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.

Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.